Veracyte Announces Third Quarter 2026 Financial Results
Globe Newswire•04/11/2026•16:05 ET
0
Key Highlights
- ➤Q3 revenue $151.8M, up 15% year over year
- ➤2026 revenue guidance narrowed to $590M-$593M from $590M-$596M
- ➤Testing revenue guidance reduced to $571M-$573M from $576M-$582M
- ➤Board authorized a share repurchase program of up to $100M
- ➤GAAP net income reached $31.5M; adjusted EBITDA was $41.2M
Expert Statements
Marc Stapley, Chief executive officer of Veracyte
“We delivered solid third quarter results supported by strong profitability and cash generation”
Marc Stapley, Chief executive officer of Veracyte
“Afirma outperformed, while Decipher Prostate volume was below our expectations.”
Marc Stapley, Chief executive officer of Veracyte
“We remain confident in the long-term outlook of our business and expect a number of evidence-based catalysts to support growth in our core franchises while also advancing our breast and bladder strategies.”
Marc Stapley, Chief executive officer of Veracyte
“As we execute on these opportunities, our differentiated financial profile enables us to continue investing in the business to drive long-term growth.”
Grew total revenue to $151.8 million and testing revenue to $146.4 million, representing 15% year-over-year growth Announces $100 million share repurchase program
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the third quarter ended September 30, 2026.
Get started
Create a free account to read the full story.